In immunotherapy, targeting MMPs may significantly enhance the cytotoxicity of T cells (CD8+ CTLs) and the ratio of cytotoxic T cells/regulatory T cells (CD8+ CTLs/Tregs) and cytokine secretion by inhibiting the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines, synergistically eliminating primary tumor growth and effectively inhibiting tumor metastasis (133, 134). The gene discussed is CD8A; the disease is neoplasm.